Norton 360 5.0.0.125 150days Fully Cracked And Trial Reset Lat Setup Free
Lutero Chaloux
In May I was looking for a parental controls solution. I installed Norton Family on my child's phone and at the same time I created an account to test out the trial. The trial account I created was myemail+n...@gmail.com. After using it for a few days, I realized that I have Family under my existing 360 subscription.
I reinstalled the app and set it up with my email which is tied to my 360 account (which is nor...@mydomain.com). Everything is working for about a month and a half, until I stop receiving email and push notifications.
Norton 360 5.0.0.125 150days fully cracked and trial reset lat setup free
- myemail+n...@gmail.com doesn't seem to be a valid account, I can't log in or reset the password (I genuinely don't remember the password, but it was something easy I created on my phone), so I can't even turn off notifications
- How is it possible that if I used Norton Family under one account one one device, then later on another device, that the device is still registered under BOTH accounts??? I have spent around 4 hours on the phone with various reps (all under the same ticket) assuring me that this is 'fixed', until I receive another parental control notification.
Call #3 (July 16) I was told that they 'removed the email'. I received a confirmation email to my nor...@mydomain.com address saying that my account was successfully updated.. Yet I received the duplicate notification later today.
Call #4 (July 16, ongoing as I type this) the technician asks 'So you want to change your email?' Before staying 'We aren't able to put other emails on tickets'.... Despite the fact that is the root issue. I'm curious to see the documentation or lack thereof on my ticket.
I asked to be transferred to a supervisor, and now after 40 minutes on call, did they finally offer to send me an email verification to my myemail+n...@gmail.com address to verify that it is me... so now I'm waiting
They came to the conclusion that the gmail account would need to be deleted on Norton's side, 10-15 days.. so I suppose I'll bump this post if there is still an issue in 15 days?
Incredibly frustrating that I need to speak to five people to have an account deleted, but still what is concerning is that how and why would it start to send emails to two entirely unrelated accounts in the first place?
Gen trademarks or registered trademarks are property of Gen Digital Inc. or its affiliates. Firefox is a trademark of Mozilla Foundation. Android, Google Chrome, Google Play and the Google Play logo are trademarks of Google, LLC. Mac, iPhone, iPad, Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Alexa and all related logos are trademarks of Amazon.com, Inc. or its affiliates. Microsoft and the Window logo are trademarks of Microsoft Corporation in the U.S. and other countries. The Android robot is reproduced or modified from work created and shared by Google and used according to terms described in the Creative Commons 3.0 Attribution License. Other names may be trademarks of their respective owners.
Faecal incontinence (FI) is a substantial health problem with a prevalence of approximately 8% in community-dwelling populations. Sacral neuromodulation (SNM) is considered the first-line surgical treatment option in adults with FI in whom conservative therapies have failed. The clinical efficacy of SNM has never been rigorously determined in a trial setting and the underlying mechanism of action remains unclear.
Secondary objectives include: measurement of established and new clinical outcomes after 1 year of therapy using new (2017 published) optimised therapy (with standardised SNM-lead placement); validation of new electronic outcome measures (events) and a device to record them, and identification of potential biological effects of SNM on underlying anorectal afferent neuronal pathophysiology (hypothesis: SNM leads to increased frequency of perceived transient anal sphincter relaxations; improved conscious sensation of defaecatory urge and cortical/subcortical changes in afferent responses to anorectal electrical stimulation (main techniques: high-resolution anorectal manometry and magnetoencephalography).
This trial will determine clinical effect size for sub-sensory chronic electrical stimulation of the sacral innervation. It will provide experimental evidence of modifiable afferent neurophysiology that may aid future patient selection as well as a basic understanding of the pathophysiology of FI.
FI leads to substantive effects on quality of life in terms of physical and emotional health; to stigmatisation and social isolation; and in older people, admission to residential care. Societal costs incurred by lost work productivity and absenteeism can be added to significant direct and indirect medical costs attributable to drug and pad usage, to specialist care, and particularly to nursing costs in older patients. Such estimates probably under-reflect the full impact of FI due to under-reporting [3]. It is estimated that treatment of urinary and FI account for at least 2% of the total UK healthcare budget [4].
Initial treatments of FI include pharmacological and behavioural therapies, the latter generally incorporating some form of biofeedback. While anecdotally these treatments appear to improve continence in a significant number of patients there is little high-quality evidence to support this [5]. Traditionally, surgical treatments focussing on anal sphincter function are offered when conservative measures fail. These can be classified into reconstructive (sphincteroplasty), augmentation (bulking agents) and neosphincter procedures (artificial sphincters, graciloplasty). These procedures are invasive, irreversible, and balance variable success rates against some risk of significant morbidity. A stoma is the final option.
Numerous observational studies show that SNM leads to substantial health gain for adults with FI with low levels of operative morbidity compared to alternative surgical strategies [6]. Reduced FI episodes correlate with objective QoL improvements [7] and SNM has been shown to be cost-effective with an ICER of 25,070 per quality-adjusted lif e year (QALY) lying within the threshold recommended by NICE as an effective use of NHS resources [7]. This systematic review, however, also highlighted the generally poor methodological quality of included studies which were almost universally single-centre retrospective or prospective clinical case series with unblinded observers and failure to report outcomes on an intention-to-treat (ITT) basis. The latter point is especially important since significant attrition bias undermines nearly all studies even including the higher-quality pivotal trial for FDA approval (a prospective multicentre US case series of 120 patients [8, 9]). Two independent publications from Europe that have reported large patient series using the ITT principle have shown less encouraging results (circa 45% long-term success) [10, 11].
Pulling the above evidence together it is clear that the clinical efficacy of SNM has never been rigorously determined in a trial setting. There is, therefore, a need for a well-designed study of SNM that seeks to determine definitive proof of clinical effect size and which notably improves on the small number of existing randomised studies and observational data. Such a study has the opportunity to embed a hypothesis-led mechanistic study.
To determine clinical efficacy of sub-sensory, chronic, low-voltage, electrical, sacral nerve-root stimulation (SNM), using a commercially-available implantable device, Medtronic Interstim in adults with FI failing conservative treatment.
Hypotheses: (1) SNM but not SHAM increases frequencies of fasting and fed perceived and unperceived transient anal sphincter relaxations (TASR) (based on prolonged high-resolution anorectal manometry recordings) to levels observed in healthy individuals; (2) SNM but not SHAM increases conscious sensation of defaecatory urge based on symptom reporting and objective measures of anorectal sensory function
* Minimum NICE standard includes; diet, bowel habit and toilet access being addressed. Medication, e.g. loperamide, advice on incontinence products, pelvic-floor muscle training, biofeedback and rectal irrigation should be offered if appropriate [4].
All patients will have been determined as clinically suitable for SNM based on clinical evaluation and subsequent multidisciplinary team discussion (as mandated by NHS England specialist commissioning guidance) or equivalent guidance in other participating EU countries.
A standard list of exclusions (disease variants; surgical fitness, specific contraindications to implantation) will be used. Note that these are routine clinical exclusions to the use of SNM rather than participation in the research. For completion:
Randomised allocation (1:1) will be performed at the time of surgery using a computer-based programme developed by the PCTU and stratified by sex and centre with block sizes of 4. The inclusion of sex as a stratification factor is justified by the potential differences in pathophysiology in the small number of male patients with significant FI [21]. Patients will be randomised prior to surgery so they enter the study even if it is not possible to implant the stimulator. If there is any problem with the online randomisation system, randomisation can be delayed up until the initial programming giving a window of 2 weeks; alternatively, emergency randomisation may be performed by an unblinded member of the coordinating team.
A nominated member of the research team or normal care clinician will have access to the programmer at the relevant fixed time points for stimulator adjustment (crossover and 6-week reprogramming). This person who will not be blind to intervention status will not otherwise be involved in the research protocol; e.g. outcomes assessments, collection of CRFs, data management.
Patients meeting the mandated response using the monopolar temporary wire or quadripolar tined lead (lead choice and duration of testing based on local surgical practice) will undergo implantation of the permanent InterStim system under general or local anaesthesia (with sedation) by trained expert colorectal surgeons following the procedural steps developed by Siegel [25] and now published as full guidance [26] (in brief: fluoroscopic-aided percutaneous insertion of 3889 lead using curved stylet and accepting position only when three out of four electrodes provide low-voltage (
b1e95dc632